Free Allergy and Immunology CME

Physicians specializing in Allergy or Dermatology.

Activity Description / Statement of Need:
In this online, self-learning activity:

Systemic mastocytosis (SM) is a heterogeneous group of disorders caused by proliferation of abnormal clonal mastocytes, which accumulate in the skin and/or other organ systems. Mastocytosis, including SM, was reclassified as a distinct disease subtype in 2016, when the World Health Organization (WHO) removed mastocytosis from the myeloproliferative neoplasm (MPN) group. The WHO defines 5 SM subtypes, ranging from indolent SM, which is associated with mild symptoms and near-normal life expectancy, to mast cell leukemia, which is an aggressive hematologic malignancy associated with median survival of less than 1 year.

Target Audience:
HCPs including: hematology/oncology specialists, allergists, and clinical immunologists, dermatologists; physician assistants, nurse practitioners, and pharmacists who practice in those areas of specialty; and any other healthcare professionals with an interest in or who may clinically encounter patients with systemic mastocytosis.

In this online, self-learning activity:

Hereditary angioedema (HAE) is a rare, debilitating, and potentially life-threatening disease due to C1-inhibitor (C1-INH) deficiency with an estimated prevalence of 5,000 people in the U.S. and over 116,000 worldwide. HAE is characterized by recurrent edema, and the cutaneous attacks can be disabling, with the skin, gastrointestinal tract, and upper airways are most commonly affected. Patients are also under persistent risk of laryngeal swelling that may prove fatal if not treated in a timely manner. The disease is classified as: HAE with normal functional C1INH protein (previously known as type III HAE) or HAE due to a deficiency of C1INH protein, with the latter further distinguished either by deficiency in both concentrations and function of C1INH (type I) or by normal levels of dysfunctional C1INH (type II). Owing to its rarity and symptomatic overlap with other conditions, patients not uncommonly experience a diagnostic delay of 8 to 10 years, putting them at a higher risk of inappropriate treatment, morbidity, and mortality.

Target Audience:
HCPs including: allergists, immunologists, emergency medicine specialists, and internists; physician assistants, nurse practitioners, and pharmacists specializing in immunology; and any other HCPs who have an interest in or otherwise clinically encounter patients with HAE.